Angioedema, ACE inhibitor and COVID-19

SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Grewal, Ekjot, Sutarjono, Bayu, Mohammed, Ibbad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482445/
https://www.ncbi.nlm.nih.gov/pubmed/32912894
http://dx.doi.org/10.1136/bcr-2020-237888
_version_ 1783580789800173568
author Grewal, Ekjot
Sutarjono, Bayu
Mohammed, Ibbad
author_facet Grewal, Ekjot
Sutarjono, Bayu
Mohammed, Ibbad
author_sort Grewal, Ekjot
collection PubMed
description SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. Finally, we also describe possible pathways that exist for SARS-CoV-2 to interact with the mechanism behind angioedema.
format Online
Article
Text
id pubmed-7482445
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74824452020-09-18 Angioedema, ACE inhibitor and COVID-19 Grewal, Ekjot Sutarjono, Bayu Mohammed, Ibbad BMJ Case Rep Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. Finally, we also describe possible pathways that exist for SARS-CoV-2 to interact with the mechanism behind angioedema. BMJ Publishing Group 2020-09-09 /pmc/articles/PMC7482445/ /pubmed/32912894 http://dx.doi.org/10.1136/bcr-2020-237888 Text en © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
spellingShingle Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Grewal, Ekjot
Sutarjono, Bayu
Mohammed, Ibbad
Angioedema, ACE inhibitor and COVID-19
title Angioedema, ACE inhibitor and COVID-19
title_full Angioedema, ACE inhibitor and COVID-19
title_fullStr Angioedema, ACE inhibitor and COVID-19
title_full_unstemmed Angioedema, ACE inhibitor and COVID-19
title_short Angioedema, ACE inhibitor and COVID-19
title_sort angioedema, ace inhibitor and covid-19
topic Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482445/
https://www.ncbi.nlm.nih.gov/pubmed/32912894
http://dx.doi.org/10.1136/bcr-2020-237888
work_keys_str_mv AT grewalekjot angioedemaaceinhibitorandcovid19
AT sutarjonobayu angioedemaaceinhibitorandcovid19
AT mohammedibbad angioedemaaceinhibitorandcovid19

Ejemplares similares